Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01777893
Registration number
NCT01777893
Ethics application status
Date submitted
24/01/2013
Date registered
29/01/2013
Date last updated
20/03/2019
Titles & IDs
Public title
Effect of Diet and Physical Activity on Incidence of Type 2 Diabetes
Query!
Scientific title
PREVention of Diabetes Through Lifestyle Intervention and Population Studies in Europe and Around the World
Query!
Secondary ID [1]
0
0
312057
Query!
Secondary ID [2]
0
0
B303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PREVIEW
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pre-diabetes
0
0
Query!
Obesity
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Behaviour - High protein/ high intensity physical activity (HP-HI)
Behaviour - High protein / moderate intensity physical activity (HP-MI)
Behaviour - Moderate protein/ high intensity physical activity (MP-HI)
Behaviour - Moderate protein/ moderate intensity physical activity (MP-MI)
Experimental: HP-HI - High protein/ high intensity physical activity
Experimental: HP-MI - High protein/ moderate intensity physical activity
Experimental: MP-HI - Moderate protein/ high intensity physical activity
Experimental: MP-MI - Moderate protein/ moderate intensity physical activity
Behaviour: High protein/ high intensity physical activity (HP-HI)
Participants follow a high protein diet and a high intensity physical activity intervention
Behaviour: High protein / moderate intensity physical activity (HP-MI)
Participants follow a high protein diet and moderate intensity physical activity intervention
Behaviour: Moderate protein/ high intensity physical activity (MP-HI)
Participants follow a moderate protein diet and a high intensity physical activity intervention
Behaviour: Moderate protein/ moderate intensity physical activity (MP-MI)
Participants follow a moderate protein diet and moderate intensity physical activity intervention
Query!
Intervention code [1]
0
0
Behaviour
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of type 2 diabetes
Query!
Assessment method [1]
0
0
For adults by OGTT
Incidence of type 2 diabetes, in high protein versus medium protein diet, measured during 3 years after baseline and based on WHO/IDF criteria:
Fasting plasma glucose (FPG) > 7.0 mmol/l (126 mg/dl) or, 75 g oral glucose tolerance test (OGTT) with FPG > 7.0 mmol/l (126 mg/dl) and/or 2 hour plasma glucose > 11.1 mmol/l (200 mg/dl) or, Glycated haemoglobin (HbA1c) > 6.5% (48 mmol/mol), or Random plasma glucose > 11.1 mmol/l (200 mg/dl) in the presence of classical diabetes symptoms.
For children and adolescents:
Change in insulin resistance at 2 years after randomization to high protein versus medium protein diet, measured by insulin resistance analysed by the homeostatic model (HOMA-IR).
Query!
Timepoint [1]
0
0
3 years
Query!
Secondary outcome [1]
0
0
Incidence of type-2 diabetes
Query!
Assessment method [1]
0
0
For children by HOMA-IR The effect of high intensity vs. moderate intensity physical activity on incidence of type 2 diabetes, based on WHO/IDF criteria (adjusted for diet).
Fasting plasma glucose (FPG) > 7.0 mmol/l (126 mg/dl) or, 75 g oral glucose tolerance test (OGTT) with FPG > 7.0 mmol/l (126 mg/dl) and/or 2 hour plasma glucose > 11.1 mmol/l (200 mg/dl) or, Glycated hemoglobin (HbA1c) > 6.5% (48 mmol/mol), or Random plasma glucose > 11.1 mmol/l (200 mg/dl) in the presence of classical diabetes symptoms.
For children and adolescents:
Change in insulin resistance at 2 years after randomization to high intensity vs. moderate intensity physical activity, analyzed by the homeostatic model (HOMA-IR).
Query!
Timepoint [1]
0
0
2 years
Query!
Secondary outcome [2]
0
0
Change in HbA1c
Query!
Assessment method [2]
0
0
A measure of average blood glucose levels
Query!
Timepoint [2]
0
0
3 years
Query!
Secondary outcome [3]
0
0
Change in body weight (kg or percent) and waist 8cm), hip (cm) and thigh circumference (cm)
Query!
Assessment method [3]
0
0
Measures of body composition
Query!
Timepoint [3]
0
0
3 years
Query!
Secondary outcome [4]
0
0
Change in body composition - fat mass and fat-free mass (kg, proportion of body weight)
Query!
Assessment method [4]
0
0
DXA, BodPod, or bio-impedance
Query!
Timepoint [4]
0
0
3 years
Query!
Secondary outcome [5]
0
0
Proportion of subjects maintaining at least 0, 5 or 10% weight loss
Query!
Assessment method [5]
0
0
Relative to initial body weight
Query!
Timepoint [5]
0
0
3 years
Query!
Secondary outcome [6]
0
0
Insulin sensitivity (e.g Matsuda Index based on the OGTT, glucose area under the curve (AUC) during OGTT, beta-cell disposition index) (OGTT only adults)
Query!
Assessment method [6]
0
0
Measures of insulin sensitivity and glucose tolerance
Query!
Timepoint [6]
0
0
3 years
Query!
Secondary outcome [7]
0
0
Risk factors for cardiovascular disease, with at least the following measures: blood pressure, heart rate, lipids (triglycerides, total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol), C-reactive protein, and liver enzymes
Query!
Assessment method [7]
0
0
Risk factors for CVD
Query!
Timepoint [7]
0
0
3 years
Query!
Secondary outcome [8]
0
0
Changes in dietary intake (4-d weighed food records)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
3 years
Query!
Secondary outcome [9]
0
0
Changes in physical activity (accelerometers and questionnaires).
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
3 years
Query!
Secondary outcome [10]
0
0
Changes in perceived quality of life and workability, habitual well-being, sleep and chronic stress, subjective appetite sensations, dietary restraint, moderators, mediators, behavioral and social environment.
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
3 years
Query!
Secondary outcome [11]
0
0
The effects of stature (height; proportion leg-length/height) in adults and changes in stature in children and adolescents, on the changes in relationship between reduction in body weight, body fat and insulin sensitivity
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
3 years
Query!
Secondary outcome [12]
0
0
Safety parameters (blood samples).
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Screening and during 3 years
Query!
Secondary outcome [13]
0
0
Adverse events and concomitant medication.
Query!
Assessment method [13]
0
0
Registration by questionnaires.
Query!
Timepoint [13]
0
0
Screening and during 3 years
Query!
Secondary outcome [14]
0
0
Compliance by urin samples for nitrogen analyses.
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
3 years
Query!
Secondary outcome [15]
0
0
In a sub-group: Metabolomic profiling.
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
3 years
Query!
Secondary outcome [16]
0
0
In a sub-group: DNA, RNA
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
3 years
Query!
Secondary outcome [17]
0
0
In a sub-group: Colon cancer risk markers
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
3 years
Query!
Secondary outcome [18]
0
0
In a sub-group: Kidney safety markers, body fat and liver-fat content.
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
3 years
Query!
Secondary outcome [19]
0
0
In a sub-group: Body and liver-fat content.
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
3 years
Query!
Secondary outcome [20]
0
0
In a sub-group: Changes in brain responses and cortical thickness
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
2 years
Query!
Secondary outcome [21]
0
0
In a sub-group: Changes in 48-h energy expenditure in a respiration chamber setting
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
3 years
Query!
Secondary outcome [22]
0
0
In a sub-group: Gut microbiome
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
3 years
Query!
Secondary outcome [23]
0
0
In a sub-group: Circulating amino acids
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
8 wks
Query!
Secondary outcome [24]
0
0
In a sub-group: Plasma mitochondrial peptides
Query!
Assessment method [24]
0
0
Query!
Timepoint [24]
0
0
8 wks
Query!
Secondary outcome [25]
0
0
In a sub-group: Insulin Growth factor 2 (IGF-II) and IGF-II receptor (IGF2R)
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
8 wks
Query!
Eligibility
Key inclusion criteria
For adults:
1. Age 25 - 70 years:
From mid 2013 - mid 2014, subjects aged 25-45 and 55-70 years were enrolled. From mid
2014, subjects aged 46-54 years were also enrolled.
2. Overweight or obesity status BMI>25 kg/m2
3. Pre-diabetes The criteria from WHO/IDF (International Diabetes Foundation) for
assessing pre-diabetes will be used as the formal inclusion criteria (at screening),
i.e. having:
Impaired Fasting Glucose (IFG): Fasting venous plasma glucose concentration 5.6 - 6.9
mmol/l or Impaired Glucose Tolerance (IGT): Venous Plasma glucose concentration of 7.8
- 11.0 mmol/l at 2 h after oral administration of 75 g glucose (oral glucose tolerance
test, OGTT), with fasting plasma glucose less than 7.0 mmol/l.
Due to potential between-lab variation (local assessments), HbA1c is not used as an
inclusion criteria in the screening.
4. Informed consent required
5. Ethnic group - No restrictions
6. Smoking - Smoking is allowed, provided subjects have not recently (within 1 month)
changed habits. However, smoking status is monitored throughout the study and used as
a confounding variable.
7. Motivation - Motivation and willingness to be randomized to any of the groups and to
do his/hers best to follow the given protocol
8. Other - Able to participate at CID's during normal working hours.
For children and adolescents:
1. Age 10-18 years
2. Age-adjusted value corresponding to BMI>25 kg/m2 (Cole et al. 2000)
3. Since the prevalence of pre-diabetes among children with overweight or obesity is low,
it is not feasible to include exclusively pre-diabetic children (according to criteria
of the IDF).
Therefore, insulin resistant over-weight/obese children will be included, defined as:
HOMA-IR = 2.0 for Tanner stage > 2. No HOMA criteria is used for Tanner stage 1 and 2.
4. Informed consent required
5. Ethnic group - No restrictions
6. Smoking - Smoking is allowed, provided subjects have not recently (within 1 month)
changed habits. However, smoking status is monitored throughout the study and used as
a confounding variable.
7. Motivation - Motivation and willingness to be randomized to any of the groups and to
do his/hers best to follow the given protocol
8. Other - Able to participate at CID's during normal school/working hours.
Query!
Minimum age
10
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Based on interview and/or questionnaire, individuals with the following problems will be
excluded:
Medical conditions as known by the subjects:
1. Diabetes mellitus (other than gestational diabetes mellitus);
2. Significant cardiovascular disease including current angina; myocardial infarction or
stroke within the past 6 months; heart failure; symptomatic peripheral vascular
disease ;
3. Systolic blood pressure above 160 mmHg and/or diastolic blood pressure above 100 mmHg
whether on or off treatment for hypertension. If being treated, no change in drug
treatment within last 3 months;
4. Advanced chronic renal impairment;
5. Significant liver disease e.g. cirrhosis (fatty liver disease allowed);
6. Malignancy which is currently active or in remission for less than five years after
last treatment (local basal and squamous cell skin cancer allowed);
7. Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other
disorder potentially causing malabsorption;
8. Previous bariatric surgery;
9. Chronic respiratory, neurological, musculoskeletal or other disorders where, in the
judgement of the investigator, participants would have unacceptable risk or difficulty
in complying with the protocol (e.g. physical activity program);
10. A recent surgical procedure until after full convalescence (investigators judgement);
11. Transmissible blood-borne diseases e.g. hepatitis B, HIV;
12. Psychiatric illness (e.g. major depression, bipolar disorder).
Medication:
13. Use currently or within the previous 3 months of prescription medication that has the
potential of affecting body weight or glucose metabolism such as glucocorticoids (but
excluding inhaled and topical steroids; bronchodilators are allowed), psychoactive
medication, epileptic medication, or weight loss medications (either prescription,
over the counter or herbal). Low dose antidepressants are allowed if they, in the
judgement of the investigator, do not affect weight or participation to the study
protocol. Levothyroxine for treatment of hypothyroidism is allowed if the participant
has been on a stable dose for at least 3 months.
Personal/Other:
14. Engagement in competitive sports;
15. Self-reported weight change of >5 % (increase or decrease) within 2 months prior to
screening;
16. Special diets (e.g. vegan, Atkins) within 2 months prior to study start. A
lacto-vegetarian diet is allowed;
17. Severe food intolerance expected to interfere with the study;
18. Regularly drinking > 21 alcoholic units/week (men), or > 14 alcoholic units/week
(women);
19. Use of drugs of abuse within the previous 12 months;
20. Blood donation or transfusion within the past 1 month before baseline or CID's;
21. Self-reported eating disorders;
22. Pregnancy or lactation, including plans to become pregnant within the next 36 months.
23. No access to either phone or Internet (this is necessary when being contacted by the
instructor's during the maintenance phase);
24. Adequate understanding of national language;
25. Psychological or behavioral problems which, in the judgement of the investigator,
would lead to difficulty in complying with the protocol.
Laboratory screening:
If all of the above criteria are satisfied, the participant is eligible for a glucose
tolerance test (blood at 0 and 120 mins), and blood glucose concentrations are
analyzed immediately (Haemocue). In addition full blood count, urea, and electrolytes
may be analyzed as a further safety evaluation. Having normal (i.e. not prediabetic)
glucose concentrations at 0 and 2h of OGTT at any stage of the study is not an
exclusion criterion.
ONLY IF the glucose tolerance test meets the entry criteria for the study, the
remaining samples are sent to the local laboratory for a safety check, with the
following exclusion criteria:
26. Hemoglobin concentration below local laboratory reference values (i.e. anemia).
27. Creatinine >1.5 times Upper Limit of Normal (local laboratory reference values).
28. Alanine Transaminase (ALT) and/or Aspartate Transaminase (AST) >3 times the Upper
Limit of Normal (local laboratory reference values) Or any other significant
abnormality on these tests which in the investigators opinion may be clinically
significant and require further assessment
29. Electrocardiography (ECG). Any abnormality which in the opinion of the investigator
might indicate undiagnosed cardiac disease requiring further assessment (e.g.
significant conduction disorder, arrhythmia, pathological Q waves). This is done in
adults 55-70 years of age.
After LCD phase (in adults):
30. Failure to reach at least 8% weight reduction during the LCD phase. This leads to
exclusion from the intervention.
Note:
- The listed inclusion and exclusion criteria are applied at screening;
- Having normal (i.e. not pre-diabetic) glucose concentrations at 0 and 2 h of OGTT at
any stage of the study after screening is not an exclusion criterion
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2018
Query!
Sample size
Target
2500
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
University of Sydney - Sydney
Query!
Recruitment postcode(s) [1]
0
0
NSW 2006 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
Bulgaria
Query!
State/province [1]
0
0
Sofia
Query!
Country [2]
0
0
Denmark
Query!
State/province [2]
0
0
Frederiksberg
Query!
Country [3]
0
0
Finland
Query!
State/province [3]
0
0
Helsinki
Query!
Country [4]
0
0
Netherlands
Query!
State/province [4]
0
0
Maastricht
Query!
Country [5]
0
0
New Zealand
Query!
State/province [5]
0
0
Auckland
Query!
Country [6]
0
0
Spain
Query!
State/province [6]
0
0
Pamplona
Query!
Country [7]
0
0
United Kingdom
Query!
State/province [7]
0
0
Nottingham
Query!
Country [8]
0
0
United Kingdom
Query!
State/province [8]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Anne Birgitte Raben
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
University of Helsinki
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Maastricht University
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
University of Nottingham
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
University of Navarra
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
Clinical Center of Endocrinology, Medical University, Sofia, Bulgaria
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Other
Query!
Name [6]
0
0
University of Sydney
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Other collaborator category [7]
0
0
Other
Query!
Name [7]
0
0
University of Auckland, New Zealand
Query!
Address [7]
0
0
Query!
Country [7]
0
0
Query!
Other collaborator category [8]
0
0
Other
Query!
Name [8]
0
0
University of Stuttgart
Query!
Address [8]
0
0
Query!
Country [8]
0
0
Query!
Other collaborator category [9]
0
0
Other
Query!
Name [9]
0
0
Swansea University
Query!
Address [9]
0
0
Query!
Country [9]
0
0
Query!
Other collaborator category [10]
0
0
Commercial sector/Industry
Query!
Name [10]
0
0
Cambridge Manufacturing Company Limited
Query!
Address [10]
0
0
Query!
Country [10]
0
0
Query!
Other collaborator category [11]
0
0
Other
Query!
Name [11]
0
0
European Union
Query!
Address [11]
0
0
Query!
Country [11]
0
0
Query!
Other collaborator category [12]
0
0
Other
Query!
Name [12]
0
0
Wageningen University
Query!
Address [12]
0
0
Query!
Country [12]
0
0
Query!
Other collaborator category [13]
0
0
Other
Query!
Name [13]
0
0
Meyers Madhus
Query!
Address [13]
0
0
Query!
Country [13]
0
0
Query!
Other collaborator category [14]
0
0
Other
Query!
Name [14]
0
0
NetUnion SARL
Query!
Address [14]
0
0
Query!
Country [14]
0
0
Query!
Other collaborator category [15]
0
0
Other
Query!
Name [15]
0
0
Terveyden Ja Hyvinvoinnin Laitos
Query!
Address [15]
0
0
Query!
Country [15]
0
0
Query!
Other collaborator category [16]
0
0
Other
Query!
Name [16]
0
0
Laval University
Query!
Address [16]
0
0
Query!
Country [16]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Type-2 diabetes is one of the fastest growing chronic diseases worldwide. This trend is
mainly driven by a global increase in the prevalence of obesity. The PREVIEW study has been
initiated to find out the most effective lifestyle-components (diet and physical activity) in
the prevention of Type-2 diabetes. The project consists of a randomized
lifestyle-intervention with the more specific aim to determine the preventative impact of a
high-protein and low-GI diet in combination with moderate or high intensity physical activity
compared with a moderate-protein and moderate GI diet in combination with the same activity
levels on the incidence of Type-2 diabetes in predisposed, pre-diabetic children, young and
older adults.
The trial will be performed in 6 EU countries (Bulgaria, Denmark, Finland, Spain,
Netherlands, UK) and Australia and New Zealand.
A total of 2,500 overweight or obese adult participants (25-70 y) as well as 150 children and
adolescents aged 10-18 y) will be recruited. All adult participants are first treated by a
low-calorie diet for 8 weeks, with an aim to reach = 8% weight reduction. Children and
adolescents are treated separately with a conventional weight-reduction diet, with-out a
specific aim for absolute weight loss.
The adult participants are randomized into two different diet interventions and two exercise
interventions for a total of 148 weeks. This period aims at preventing Type-2 diabetes by
weight-maintenance (prevention of relapse in reduced body weight) and by independent
metabolic effects of diet and physical activity.
The primary endpoint of the study is the incidence of Type-2 diabetes in the adults during 3
years (156 weeks) according to diet (high protein/low-GI versus moderate protein/moderate-GI,
adjusted for physical activity), based on a 75 g oral glucose tolerance test and/or HbA1c.
For children and adolescents:
Change in insulin resistance at 2 years after randomization to high protein versus moderate
protein diet, measured by insulin resistance analyzed by the homeostatic model (HOMA-IR) as
well as physiological improvement of health with respect to pre-diabetic characteristics.
Our hypothesis is that a high-protein, low-GI diet will be superior in preventing type-2
diabetes, compared with a moderate protein, moderate GI diet, and that high-intensity
physical activity will be superior compared to moderate-intensity physical activity.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01777893
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Thomas M Larsen, Ass. Prof.
Query!
Address
0
0
University of Copenhagen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01777893
Download to PDF